Products for Research Use Only

ATI-2341 (TFA)

CAT: 0804-HY-P0172A-01Size: 1 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-P0172A-01Size:1 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
ATI-2341 is a potent and functionally selective allosteric agonist of C-X-C chemokine receptor type 4 (CXCR4), which functions as a biased ligand, favoring Gαi activation over Gα13. ATI-2341 activates the inhibitory heterotrimeric G protein (Gi) to promote inhibition of cAMP production and induce calcium mobilization. ATI-2341 is a potent and efficacious mobilizer of bone marrow polymorphonuclear neutrophils (PMNs) and hematopoietic stem and progenitor cells (HSPCs) [1][2].
UNSPSC
12352209
Target
CXCR
Type
Peptides
Related Pathways
GPCR/G Protein; Immunology/Inflammation
Applications
COVID-19-immunoregulation
Field of Research
Cancer; Inflammation/Immunology; Endocrinology
Assay Protocol
https://www.medchemexpress.com/ati-2341-tfa.html
Purity
98.08
Solubility
DMSO : 50 mg/mL (ultrasonic)
Smiles
O=C(N[C@@H](CCCNC(N)=N)C(N[C@H](C(O)=O)CC(C)C)=O)[C@@H](NC([C@H](CCCCN)NC([C@H](CC(O)=O)NC([C@@]([C@H](O)C)([H])NC([C@H](CCSC)NC([C@H](CO)NC([C@H](CCCNC(N)=N)NC([C@H](CC(C)C)NC([C@H](CCCCN)NC([C@H](CCCCN)NC([C@H](CCC(N)=O)NC([C@@H](NC(CNC([C@H](CCSC)NC(CCCCCCCCCCCCCCC)=O)=O)=O)CC1=CC=C(O)C=C1)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)CC2=CC=C(O)C=C2.OC(C(F)(F)F)=O.[x]
Molecular Formula
C104H178N26O25S2.xC2HF3O2
Molecular Weight
2256.82 (free base)
References & Citations
[1]Quoyer J, et al. Pepducin targeting the C-X-C chemokine receptor type 4 acts as a biased agonist favoring activation of the inhibitory G protein. Proc Natl Acad Sci U S A. 2013 Dec 24;110 (52) :E5088-97.|[2]Tchernychev B, et al. Discovery of a CXCR4 agonist pepducin that mobilizes bone marrow hematopoietic cells. Proc Natl Acad Sci U S A. 2010 Dec 21;107 (51) :22255-9.
Shipping Conditions
Blue Ice
Storage Conditions
-80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)
Scientific Category
Peptides
Clinical Information
No Development Reported